Helsingin Ja Uudenmaan Sairaanhoitopiirin Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2017
NCT03162653
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

allopurinol (zyloprim) (1 trial)

mannitol (Osmitrol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 3)

Brain Injuries (Phase 3)

Hypoxia (Phase 3)

Hypoxia, Brain (Phase 3)

Hypoxia-Ischemia, Brain (Phase 3)

Infant, Newborn, Diseases (Phase 3)

Ischemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2